Figure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Authors:

Abstract
Kaplan-Meier curves for overall survival. (A) PD-1 monotherapy by driver class. (B) nivolumab plus ipilimumab by driver class. (C) PD-1 monotherapy by primary site of melanoma. (D) nivolumab plus ipilimumab by primary site of melanoma.